Open AccessUse of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Author(s) -
Elena V. Ivanova,
Mari Kuraguchi,
Man Xu,
Andrew Portell,
Luke J. Taus,
Irmina Diala,
Alshad S. Lalani,
Jihyun Choi,
Emily S. Chambers,
Shuai Li,
Shengwu Liu,
Ting Chen,
Thanh U. Barbie,
Geoffrey R. Oxnard,
Jacob J. Haworth,
KwokKin Wong,
Suzanne E. Dahlberg,
Amir A. Aref,
David A. Barbie,
Magda Bahcall,
Cloud P. Paweletz,
Pasi A. Jänne
Publication year - 2020
Publication title -
clinical cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.427
H-Index - 324
eISSN - 1557-3265
pISSN - 1078-0432
DOI - 10.1158/1078-0432.ccr-19-1844
Subject(s) - neratinib , ex vivo , afatinib , cancer research , trastuzumab , medicine , gefitinib , in vivo , lapatinib , cancer , lung cancer , pharmacology , pathology , biology , epidermal growth factor receptor , breast cancer , microbiology and biotechnology
Evaluating drug responses using primary patient-derived cells ex vivo represents a potentially rapid and efficient approach to screening for new treatment approaches. Here, we sought to identify neratinib combinations in HER2 mutant non-small cell lung cancer (NSCLC) patient x enograft- d erived o rganotypic s pheroids (XDOTS) using a short-term ex vivo system.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom